Daewoong Pharmaceutical and AstraZeneca Korea have signed a co-promotion partnership accord to market the latter’s Forxiga and Xigduo, both diabetes type 2 treatment, Daewoong said Thursday.
The contract is an extension of the previous agreement between the two companies on March 1, under which the two companies agreed that Daewoong would be in charge of domestic distribution of the two drugs. Under the newly updated contract, Daewoong will now take up additional responsibilities in marketing and sales.
“Based on the differentiated verification 4-step marketing strategy and strong sales force, the company plans to expand market shares for AstraZeneca’s superior products Forxiga and Xigduo,” a company official said.
Forxiga is a sodium-glucose transport protein 2 (SGLT-2)-inhibitor that helps the kidney remove blood glucose and excrete it through urine. It has an excellent blood glucose lowering effect and an additional advantage in weight loss.
Also, in a recent real-world study presented at the American Heart Association 2018 convention in Orlando, U.S., Forxiga reduced the all-cause mortality rate for approximately 340,000 type 2 diabetes patients.
With the new partnership, Daewoong now markets four of AstraZeneca Korea’s products – Forxiga, Xigduo, Crestor and Nexium.
<© Korea Biomedical Review, All rights reserved.>